



Published in final edited form as:

Nat Genet. 2015 February ; 47(2): 164–171. doi:10.1038/ng.3185.

Identification of six new susceptibility loci for invasive epithelial ovarian cancer

A full list of authors and affiliations appears at the end of the article.

Genome-wide association studies (GWAS) have identified 12 epithelial ovarian cancer (EOC) susceptibility alleles. The pattern of association at these loci is consistent in *BRCA1* and *BRCA2* mutation carriers who are at high EOC risk. After imputation to the 1000 Genomes Project data, we assessed associations of 11 million genetic variants with EOC risk from 15,397 cases unselected for family history and 30,816 controls, 15,252 *BRCA1* mutation carriers and 8,211 *BRCA2* mutation carriers (3,096 with ovarian cancer), and combined the results in a meta-analysis. This new study design yielded increased statistical power, leading to the discovery of six new EOC susceptibility loci. Variants at 1p36 (nearest gene *WNT4*), 4q26 (*SYNPO2*), 9q34.2 (*ABO*) and 17q11.2 (*ATAD5*) were associated with

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms

Correspondence to: Karoline B. Kuchenbaecker; Susan J. Ramus; Jonathan Tyrer.

⁴³A full list of members appears in the supplementary notes.

⁴⁸on behalf of the German Consortium of Hereditary Breast and Ovarian Cancer (GC-HBOC).

Author Contributions

Writing group: K.B.K., A.C.A., G.C-T., S.J.R, J.Beasley, P.P.P., S.G. Performed statistical analyses for CIMBA: K.B.K. Performed statistical analyses for OCAC: J.T. Performed the meta-analyses: K.B.K. CIMBA database management: L.McG. and D.B. Supervised CIMBA statistical analyses and CIMBA data management: A.C.A. Supervised OCAC statistical analyses: P.P.P. Initiated and coordinated CIMBA: G.C-T. Coordinated OCAC: A.Berchuck and P.P.P. Conceived and coordinated the synthesis of the iCOGS array: D.F.E. Co-ordinated iCOGS genotyping : J.S., K.Offit, F.J.C. iCOGS genotyping, calling and quality control: J.M.Cunningham, J.D., A.Lee, P.S., D.F.E., G.C-T., Provided DNA samples and/or phenotypic data: S.J.R., J.T., A.Lee, H.C.S., K.L., S.Healey, J.M.L., T.J.S., Y.G.L., T.P., Y.B., Q.L., S.C., D.H., A.Miron, M.Southey, M.B.T., D.E.G., S.S.B., R.J., C.M.D., E.J.vanR., S.L.N., Y.C.D., T.V.O.H, L.J., A-M.G., B.E., J.D., J.Benitez, A.O., M.J.G., I.Komenka, J.N.W., P.G., P.P., L.Bernard, A.V., B.B., B.P., S.Manoukian, P.R., L.P., L.O., F.F., I.Konstantopolous, J.Garber, D.F., J.Perkins, R.P., S.E., EMBRACE, A.K.G., R.K.S., A.Meindl, C.E., C.S., O.M.S., GEMO, F.D., S.Mazoyer, D.S-L., K.Claes, K.D.L., J.Kirk, G.C.R., M.Piedmonte, D.M.O'M., M.de la H., T.C., K.A., H.Neivalinna, J.M.Collee, M.A.Rookus, J.C.O., F.B.L.H., HEBON, E.O., O.D., I.B., J.Brunet, C.L., M.A.P., A.Jakubowska, J.Gronwald, J.Lubinski, G.S., R.B.B., M.Plante, J.S., P.S., M.M., S.Tognazzo, M.R.T., kConFab, V.S.P., X.Wang, N.L., C.I.S., N.K., J.V., C.A.A., G.P., A.Berger, C.F.S., M-K.T., C.M.P., M.H.G., P.L.M., G.R., A.M.M., S.Tchatchou, I.L.A., G.G., A.E.T., U.B.J., T.A.K., M.T., A.Bojesen, J.Z., E.F., Y.L., M.Soller, A.Liljegren, B.A., Z.E., M.S-A., O.I.O., R.L.N., T.R.R., K.L.N., S.M.D., K.H.L., B.Y.K., C.W., J.Lester, ACS, AOCS, P.W., A.H., A.B.E., M.W.B., P.A.F., D.Lambrechts, E.V.N., I.V., S.Lambrechts, E.D., J.A.D., K.G.W., M.A.Rossing, A.R., J.C-C., S.W-G., U.E., K.B.M., K.Odunsi, L.S., S.Lele, L.R.W., M.T.G., P.J.T., Y.B.S., I.B.R., M.D., P.Hillemans, T.D., N.A., N.B., A.Leminen, L.M.P., R.B., F.M., J.L.K., R.P.E., R.B.N., A.du B., F.H., I.S., P.Harter, K.M., S.Hosono, S.O., A.Jensen, S.K.K., E.H., H.N.H., M.A.N.A., S-H.T., Y-L.W., B.L.F., E.L.G., J.M.Cunningham, R.A.V., F.B., G.G.G., D.Liang, M.A.T.H., X.Wu, D.A.L., M.B., A. Berchuck, E.S.I., J.M.S., P.C., R.P.W., D.W.C., K.L.T., E.M.P., S.S.T., E.V.B., I.O., S.H.O., C.K., H.B.S., I.L.T., L.Bjorge, A.M.van A., K.K.H.A., L.A.K., L.F.A.G.M., M.K., A.B-W., L.E.K., L.S.C., N.D.L., C.C., H.Y., J.Lissowska, L.A.B., N.W., C.H., L.L., L.N., H.B., H.S., D.E., I.G.C., I.McN., J.Paul, K.Carty, N.S., R.G., A.S.W., J.H.R., V.McG., W.S., B-T.J., W.Z., X-O.S., Y-T.G., B.R., H.A.R., J.R.McL., S.A.N., A.N.M., A.C., H-Y.L., J.P-W., T.A.S., Y-Y.T., Z.C., A.Z., H.A-C., A.G-M., U.M., P.Harrington, A.W.L., A.H.W., C.L.P., G.C., M.C.P., A.D-M., A.T., I.K.R., J.Kuprynjczyk, M.F., H.Noushmehr, D.F.E., K.Offit, F.J.C., S.G., P.P.P., A.C.A., G.C-T. All authors read and approved the final manuscript.

Websites

Nature Publishing Group. *Nature Genetics* - iCOGS, <http://www.nature.com/icogs/>

The Cancer Genome Atlas Project - <http://cancergenome.nih.gov/>

The cBio Cancer Genomics Portal - <http://www.cbioportal.org/>

Pupasuite 3.1 -<http://pupasuite.bioinfo.cipf.es>

CIMBA QC guidelins-<http://ccge.medschl.cam.ac.uk/consortia/cimba/members/data%20management/CIMBA%20and%20BCAC%20Quality%20Control%20November%202008%20v2.doc>

EOC risk, and at 1p34.3 (*RSP01*) and 6p22.1 (*GPX6*) specifically with the serous EOC subtype, at $p < 5 \times 10^{-8}$. Incorporating these variants into risk assessment tools will improve clinical risk predictions for *BRCA1/2* mutation carriers.

The risk of developing invasive EOC is higher than the population average for relatives of women diagnosed with the disease^{1,2}, indicating the importance of genetic factors in disease susceptibility. Approximately 25% of the familial aggregation of EOC is explained by rare, high-penetrance alleles of *BRCA1* and *BRCA2*³. Furthermore, population-based GWAS have identified common variants associated with invasive EOC at 11 loci⁴⁻⁹ but only six have also been evaluated in *BRCA1* and/or *BRCA2* mutation carriers. All loci displayed associations in mutation carriers that were consistent with the associations observed in the general population¹⁰⁻¹². In addition, the 4q32.3 locus is associated with EOC risk for *BRCA1* mutation carriers only¹³. However, the common genetic variants explain less than 3.1% of the excess familial risk of EOC so additional susceptibility loci are likely to exist.

Women diagnosed with EOC and unaffected women from the general population ascertained through the Ovarian Cancer Association Consortium (OCAC)¹⁴ and *BRCA1* and *BRCA2* mutation carriers from the Consortium of Investigators of Modifiers of *BRCA1/2* (CIMBA)¹⁵ were genotyped as part of the Collaborative Oncological Gene-environment Study (COGS) using the iCOGS custom array. In addition, data were available for cases and controls from three EOC GWAS. We first evaluated whether the EOC susceptibility loci at 8q21.13, 10p12.31, 17q12, 5p15.33, and 17q21.31 recently identified by OCAC⁷⁻⁹ also show evidence of association in *BRCA1* and *BRCA2* mutation carriers. Using data from >200,000 genotyped SNPs^{7,13,16}, we performed imputation of common variants from the 1000 Genomes Project data¹⁷ and evaluated the associations of these SNPs with invasive EOC risk in OCAC and in *BRCA1* and *BRCA2* mutation carriers from CIMBA. Given the strong evidence for a significant overlap in loci predisposing to EOC in the general population and those associated with risk in *BRCA1* and *BRCA2* mutation carriers, we carried out a meta-analysis of the EOC risk associations in order to identify novel EOC susceptibility loci.

Genotype data were available for imputation on 15,252 *BRCA1* mutation carriers and 8,211 *BRCA2* mutation carriers, of whom 2,462 and 631, respectively, were affected with EOC^{13,16}. From OCAC, genotyping data were available from 15,437 women with invasive EOC (including 9,627 with serous EOC) and 30,845 controls from the general population⁷. Imputation was performed separately for *BRCA1* carriers, *BRCA2* carriers, OCAC-COGS samples and the three OCAC GWAS (Supplementary Tables 1-2; Supplementary Fig. 1; Supplementary Fig. 2). The meta-analysis was based on 11,403,952 SNPs (Supplementary Fig. 3).

Of five EOC susceptibility loci that have not yet been evaluated in mutation carriers, two were associated with EOC risk for both *BRCA1* and *BRCA2* mutation carriers at $p < 0.05$ (10p12.31 and 17q21.31) (Supplementary Table 3). Overall, seven of the twelve known EOC susceptibility loci provided evidence of association in *BRCA1* mutation carriers and six were associated in *BRCA2* mutation carriers. However, with the exception of 5p15.33 (*TERT*), all loci had hazard ratio (HR) estimates in *BRCA1* and *BRCA2* carriers that were in

the same direction as the odds ratio (OR) estimates for serous subtype EOC from OCAC (Fig. 1). Analysing the associations jointly in *BRCA1* and *BRCA2* carriers and serous EOC in OCAC provided stronger evidence of association, with smaller p-values for eight of the susceptibility variants compared to the analysis in OCAC alone.

Using the imputed genotypes, we observed no novel associations at $p < 5 \times 10^{-8}$ in the analysis of associations in *BRCA1* or *BRCA2* mutation carriers separately. However, we identified seven previously unreported associations (p -values $< 5 \times 10^{-8}$) in either OCAC alone, the meta-analysis of EOC associations in *BRCA1*, *BRCA2* carriers and OCAC, or in the meta-analysis in *BRCA1* and *BRCA2* carriers and serous EOC in OCAC (Supplementary Fig. 4; Supplementary Tables 4–5). SNPs in six of these loci remained genome-wide statistically significant after re-imputing genotypes with imputation parameters set to maximise accuracy (Table 1; Fig. 1). SNPs at 17q11.2 (near *ATAD5*) were found to be associated with invasive EOC in OCAC ($p < 5 \times 10^{-8}$) (Table 1). For the lead SNP, chr17:29181220:I, the estimated HR estimate for *BRCA1* mutation carriers was significantly different from the estimate in OCAC ($p = 0.005$); the association for *BRCA2* carriers was consistent with the OCAC OR estimate (*BRCA2-OCAC* meta-analysis $p = 2.6 \times 10^{-9}$). SNPs at four loci were associated at $p < 5 \times 10^{-8}$ with risk of all invasive EOC in the meta-analysis (Supplementary Fig. 5): 1p36, 1p34.3, 4q26, and 9q34.2. At 1p34.3, the most strongly associated SNP, rs58722170, displayed stronger associations in the meta-analysis of serous EOC for OCAC ($p = 2.7 \times 10^{-12}$). In addition, SNPs at 6p22.1 were associated at genome-wide significance level in the meta-analysis of associations with serous EOC ($p = 3.0 \times 10^{-8}$), but not in the meta-analysis of all invasive EOC associations ($p = 6.8 \times 10^{-6}$).

The most significantly associated SNP at each of the six novel loci had high imputation accuracy (r^2 0.83). At the 1p34.3, 1p36, and 6p22.1 loci, there was at least one genome-wide significant genotyped SNP correlated with the lead SNP (pairwise r^2 0.73) (Supplementary Table 6; Supplementary Fig. 5; Supplementary Note). We genotyped the leading (imputed) SNPs of the three other loci in a subset of the samples using iPLEX (Supplementary Note). The correlations between the expected allele dosages from the imputation and the observed genotypes for the variants at 4q26 and 9q34.2, ($r^2 = 0.90$ and $r^2 = 0.84$, respectively) were consistent with the estimated imputation accuracy (0.93 and 0.83 for CIMBA samples). The lead SNP at 17q11.2 failed iPLEX design. However, the risk allele is highly correlated with the AA haplotype of two genotyped variants on the iCOGS array (rs9910051 and rs3764419). This haplotype is strongly associated with ovarian cancer risk in the subset of samples genotyped using iCOGS (*BRCA2-OCAC* meta-analysis $p = 8.6 \times 10^{-8}$ for haplotype, and $p = 1.8 \times 10^{-8}$ for chr17:29181220:I) (Supplementary Table 7).

None of the regions contained additional SNPs that displayed EOC associations at $p < 10^{-4}$ in OCAC, *BRCA1* carriers or *BRCA2* carriers in multi-variable analyses adjusted for the lead SNP in each region, indicating that they each contain only one independent set of correlated highly associated variants (iCHAV). Relative to the 1000 Genomes Project data, we had genotyped or imputed data covering 91% of the genetic variation at 1p36, 84% at 1p34.3 and 83% at 4q26. The other three novel loci had coverage of less than 80% (Supplementary Note). There was evidence for heterogeneity at $p < 0.05$ in the associations with histological

subtype in OCAC for the lead SNPs at 1p34.4 and 6p22.1, but not for at 1p36, 4q26, 9q34.2 and 17q11.2 (Table 2).

We carried out a competing risks association analysis in *BRCA1* and *BRCA2* mutation carriers in order to investigate whether these loci are also associated with breast cancer risk for mutation carriers (Supplementary Note). We used the most strongly associated genotyped SNPs for this purpose because the statistical method requires actual genotypes¹⁸. The EOC HR estimates were consistent with the estimates from the main analysis for all SNPs (Supplementary Table 8). None of the SNPs displayed associations with breast cancer risk at $p < 0.05$.

At each of the six loci, we identified a set of SNPs with odds of less than 100 to 1 against being the causal variant; most are in non-coding DNA regions (Supplementary Table 9). None were predicted to have likely deleterious functional effects although some lie in or near chromatin biofeatures in fallopian tube and ovarian epithelial cells which may represent the functional regulatory targets of the risk SNPs (Table 3; Supplementary Table 10). We also evaluated the protein coding genes in each region for their role in EOC development, and as candidate susceptibility gene targets. Molecular profiling data from 496 HGSOCs performed by The Cancer Genome Atlas (TCGA) indicated frequent loss/deletion at four risk loci (1p36, 4q26, 9q34.2 and 17q11.2) (Supplementary Table 11). Consistent with this, *WNT4* and *ABO* were significantly down-regulated in ovarian tumours while *ATAD5* was up-regulated. Somatic coding sequence mutations in the six genes nearest the index SNPs were rare. We performed expression quantitative trait locus (eQTL) analysis in a series of 59 normal ovarian tissues (Supplementary Table 12) to evaluate the gene nearest the top ranked SNP at each locus. For the five genes expressed in normal cells, we found no statistically significant eQTL associations for any of the putative causal SNPs at each locus; neither did we find any significant tumour-eQTL associations for these genes based on data from TCGA (Supplementary Table 12). At the 1p36 locus, the most strongly associated variant, rs56318008, is located in the promoter region of *WNT4* which encodes a ligand in the WNT signal transduction pathway, critical for cell proliferation and differentiation. Using a luciferase reporter assay we found no effect of these putatively causal SNPs on *WNT4* transcription in iOSE4 normal ovarian cells (Fig. 2). Some of the putative causal SNPs at 1p36 are located in *CDC42* and *LINC00339*, and several are in putative regulatory domains in ovarian tissues (Supplementary Table 10; Fig. 2). *CDC42* is known to play a role in migration and signalling in ovarian and breast cancer^{19,20}. SNPs at 1p36 are also associated with increased risk of endometriosis and *WNT4*, *CDC42* and *LINC00339* have all been implicated in endometriosis²¹, a known risk factor for endometrioid and clear cell EOC²².

The strongest associated variant at 1q34, rs58722170, is located in *RSPO1*, which encodes R-spondin 1, a protein involved in cell proliferation (Supplementary Fig. 6). *RSPO1* is important in tumorigenesis and early ovarian development^{23,24}, and regulates *WNT4* expression in the ovaries²⁵. *SYNPO2* at 4q26 encodes myopodin which is involved in cell motility and growth²⁶ and has a reported tumour suppressor role²⁷⁻³⁰. rs635634 is located upstream of the *ABO* gene (Supplementary Fig. 7). A moderately correlated variant (rs505922, $r^2=0.52$) determines ABO blood group and is associated with increased risk of pancreatic cancer^{31,32}. Previous studies in OCAC also showed a modestly increased risk of

EOC for individuals with the A blood group³³. The moderate correlation between rs635634 and rs505922 and considerably weaker EOC association of rs505922 ($p=1.2\times 10^{-5}$) suggests that the association with blood group is probably not driving the association with risk. The indel, 17:29181220:I, at 17q11.2 is located in *ATAD5* which acts as a tumour suppressor gene^{34–36} (Supplementary Fig. 8). *ATAD5* modulates the interaction between RAD9A and BCL2 in order to induce DNA damage related apoptosis. Finally, rs116133110, at 6p22.1, lies in *GPX6* which has no known role in cancer.

The six novel loci reported in this study increase the number of genome-wide significant common variant loci so far identified for EOC to 18. Taken together, these explain approximately 3.9% of the excess familial relative risk of EOC in the general population, and account for approximately 5.2% of the EOC polygenic modifying variance in *BRCA1* mutation carriers and 9.3% in *BRCA2* mutation carriers. The similarity in the magnitude of associations between *BRCA1* and *BRCA2* carriers and population-based studies suggests a general model of susceptibility whereby *BRCA1* and *BRCA2* mutations and common alleles interact multiplicatively on the relative risk scale for EOC³⁷. This model predicts large differences in absolute EOC risk between individuals carrying many alleles and individuals carrying few risk alleles of EOC susceptibility loci for *BRCA1* and *BRCA2* mutation carriers^{13,16}. Incorporating EOC susceptibility variants into risk assessment tools will improve risk prediction and may be particularly useful for *BRCA1* and *BRCA2* mutation carriers.

METHODS

Study populations

We obtained data on *BRCA1* and *BRCA2* mutation carriers through CIMBA. Eligibility in CIMBA is restricted to females 18 years or older with pathogenic mutations in *BRCA1* or *BRCA2*. The majority of the participants were sampled through cancer genetics clinics¹⁵, including some related participants. Fifty-four studies from 27 countries contributed data. After quality control, data were available on 15,252 *BRCA1* mutation carriers and 8,211 *BRCA2* mutation carriers, of whom 2,462 and 631, respectively, were affected with EOC (Supplementary Table 1).

Data were available for the stage 1 of three population-based EOC GWAS. These included 2,165 cases and 2,564 controls from a GWAS from North America (“US GWAS”)³⁹, 1,762 cases and 6,118 controls from a UK-based GWAS (“UK GWAS”)⁶, and 441 cases and 441 controls from the Mayo GWAS. Furthermore, 11,069 cases and 21,722 controls were genotyped using the iCOGS array (“OCAC-iCOGS” stage data). Overall, 43 studies from 11 countries provided data on 15,347 women diagnosed with invasive epithelial EOC, 9,627 of whom were diagnosed with serous EOC, and 30,845 controls from the general population.

All subjects included in this analysis were of European descent and provided written informed consent as well as data and blood samples under ethically approved protocols. Further details of the OCAC and CIMBA study populations as well as the genotyping, quality control and statistical analyses have been described elsewhere^{7,13,16}.

Genotype data

Genotyping and imputation details for each study are shown in Supplementary Table 1.

Confirmatory genotyping of imputed SNPs

To evaluate the accuracy of the imputation of the SNPs we found to be associated with EOC risk, we genotyped rs17329882 (4q26) and rs635634 (9q34.2) in a subset of 3,541 subjects from CIMBA using Sequenon's iPLEX technology. The lead SNP at 17q11.2, chr17:29181220:I failed iPLEX design. We performed quality control of the iPLEX data according to the CIMBA guidelines. After quality control, we used the imputation results to generate the expected allele dosage for each genotyped sample and computed the Pearson product-moment correlation coefficient between the expected allele dosage and the observed genotype. The squared correlation coefficient was compared to the imputation accuracy as estimated from the imputation.

Quality control of GWAS and iCOGS genotyping data

We carried out quality control separately for *BRCA1* carriers, *BRCA2* carriers, the three OCAC GWAS, and OCAC-iCOGS samples, but quality criteria were mostly consistent across studies. We excluded samples if they were not of European ancestry, if they had a genotyping call rate < 95%, low or high heterozygosity, if they were not female or had ambiguous sex, or were duplicates (cryptic or intended). In OCAC studies, one individual was excluded from each pair of samples found to be first-degree relatives and duplicate samples between the iCOGS stage and any of the GWAS were excluded from the iCOGS data. SNPs were excluded if they were monomorphic, had call rate < 95%, showed evidence of deviation from Hardy-Weinberg equilibrium or had low concordance between duplicate pairs. For the Mayo GWAS and the UK GWAS, we also excluded rare SNPs (MAF < 1% or allele count < 5, respectively). We visually inspected genotype cluster plots for all SNPs with $P < 10^{-5}$ from each of the newly identified loci. We used the R GenABEL library version 1.6.7 for quality control⁴⁰.

Genotype data were available for analysis from iCOGS for 199,526 SNPs in OCAC-iCOGS, 200,720 SNPs in *BRCA1* mutation carriers, and 200,908 SNPs in *BRCA2* mutation carriers. After QC, for the GWAS, data were available on 492,956 SNPs for the US GWAS, 543,529 SNPs for the UK GWAS and 1,587,051 SNPs for the Mayo GWAS (Supplementary Table 2).

Imputation

We performed imputation separately for *BRCA1* carriers, *BRCA2* carriers, OCAC-iCOGS samples and each of the OCAC GWAS. We imputed variants from the 1000 Genomes Project data using the v3 April 2012 release¹⁷ as the reference panel. For OCAC-iCOGS, the UK GWAS and the Mayo GWAS, imputation was based on the 1000 Genomes Project data with singleton sites removed. To improve computation efficiency we initially used a two-step procedure, which involved pre-phasing in the first step and imputation of the phased data in the second. We carried out pre-phasing using the SHAPEIT software⁴¹. We used the IMPUTE version 2 software for the subsequent imputation⁴² for all studies with the

exception of the US GWAS for which the MACH algorithm implemented in the minimac software version 2012.8.15, mach version 1.0.18 was used. To perform the imputation we divided the data into segments of approximately 5Mb each. We excluded SNPs from the association analysis if their imputation accuracy was $r^2 < 0.3$ or their minor allele frequency (MAF) was < 0.005 in *BRCA1* or *BRCA2* carriers or if their accuracy was $r^2 < 0.25$ in OCAC-iCOGS, the UK GWAS, UK GWAS or Mayo GWAS.

We performed more accurate imputation for the regions around the novel EOC loci from the joint analysis of the data from *BRCA1* and *BRCA2* carriers and the general population (any SNP with $P < 5 \times 10^{-8}$). The boundaries of these regions were set ± 500 kb from any significantly associated SNP in the region. As in the first run, the 1000 Genomes Project data v3 were used as the reference panel and the software IMPUTE2 was applied. However, for the second round of imputation, we imputed genotypes without pre-phasing in order to improve accuracy. To further increase the imputation accuracy we changed some of the default parameters in the imputation procedure. These included an increase of the MCMC iterations to 90 (out of which the first 15 were used as burn-in), an increase of the buffer region to 500kb and an increase of the number of haplotypes used as templates when phasing observed genotypes to 100. These changes were applied consistently for all data sets.

Statistical analyses

Association analyses in the unselected ovarian cancer cases and controls from OCAC—We evaluated the association between genotype and disease using logistic regression by estimating the associations with each additional copy of the minor allele (log-additive models). The analysis was adjusted for study and for population substructure by including the eigenvectors of the first five ancestry specific principal components as covariates in the model. We used the same approach to evaluate the SNP associations with serous ovarian cancer after excluding all cases with any other or with unknown tumour subtype. For imputed SNPs we used expected dosages in the logistic regression model to estimate SNP effect sizes and p-values. We carried out analyses separately for OCAC-iCOGS and the three GWAS and pooled thereafter using a fixed effects meta-analysis. We carried out the analysis of re-imputed genotypes of putative novel susceptibility loci jointly for the OCAC-iCOGS and GWAS samples. All results are based on the combined data from iCOGS and the three GWAS. We used custom written software for the analysis.

Associations in *BRCA1* and *BRCA2* mutation carriers from CIMBA—We carried out the ovarian cancer association analyses separately for *BRCA1* and *BRCA2* mutation carriers. The primary analysis was carried out within a survival analysis framework with time to ovarian cancer diagnosis as the endpoint. Mutation carriers were followed until the age of ovarian cancer diagnosis, or risk-reducing salpingo-oophorectomy (RRSO) or age at last observation. Breast cancer diagnosis was not considered as a censoring event. In order to account for the non-random sampling of *BRCA1* and *BRCA2* mutation carriers with respect to their disease status we conducted the analyses by modelling the retrospective likelihood of the observed genotypes conditional on the disease phenotype¹⁸. We assessed the associations between genotype and risk of ovarian cancer using the 1 degree of freedom

score test statistic based on the retrospective likelihood^{18,43}. To account for the non-independence among related individuals in the sample, we used an adjusted version of the score test statistic, which uses a kinship adjusted variance of the score⁴⁴. We evaluated associations between imputed genotypes and ovarian cancer risk using a version of the score test as described above but with the posterior genotype probabilities replacing the genotypes. All analyses were stratified by the country of origin of the samples.

We carried out the retrospective likelihood analyses in CIMBA using custom written functions in Fortran and Python. The score test statistic was implemented in R version 3.0.1⁴⁵.

We evaluated whether there is evidence for multiple independent association signals in the region around each newly identified locus by evaluating the associations of genetic variants in the region while adjusting for the SNP with the smallest meta-analysis p-value in the respective region. This was done separately for *BRCA1* carriers, *BRCA2* carriers and OCAC.

For one of the novel associations, it was not possible to confirm the imputation accuracy of the lead SNP chr17:29181220:I at 17q11.2 through genotyping. Therefore, we inferred two-allele haplotypes for rs9910051 and rs3764419, highly correlated with the lead SNP ($r^2=0.95$), using an in-house program. These variants were genotyped on the iCOGS array and therefore this analysis was restricted to 14,733 ovarian cancer cases and 9,165 controls from OCAC-COGS, and 8,185 *BRCA2* mutation carriers that had available genotypes for both variants based on iCOGS. The association between the AA haplotype and risk was tested using logistic regression in OCAC and using Cox regression in *BRCA2* mutation carriers.

Meta-analysis—We conducted a meta-analysis of the EOC associations in *BRCA1*, *BRCA2* carriers and the general population for genotyped and imputed SNPs using an inverse variance approach assuming fixed effects. We combined the logarithm of the per-allele hazard ratio estimate for the association with EOC risk in *BRCA1* and *BRCA2* mutation carriers and the logarithm of the per-allele odds ratio estimate for the association with disease status in OCAC. For the associations in *BRCA1* and *BRCA2* carriers, we used the kinship adjusted variance estimator⁴⁴ which allows for inclusion of related individuals in the analysis. We only used SNPs with results in OCAC and in at least one of the *BRCA1* or the *BRCA2* analyses. We carried out two separate meta-analyses, one for the associations with EOC in *BRCA1* carriers, *BRCA2* carriers and EOC in OCAC, irrespective of tumour histological subtype, and a second using only the associations with serous EOC in OCAC. The number of *BRCA1* and *BRCA2* samples with tumour histology information was too small to allow for subgroup analyses. However, previous studies have demonstrated that the majority of EOCs in *BRCA1* and *BRCA2* mutation carriers are high-grade serous^{49–53}. Meta-analyses were carried out using the software “metal”, 2011-03-25 release⁵⁴.

Candidate causal SNPs in each susceptibility region—In order to identify a set of potentially causal variants we excluded SNPs with a likelihood of being causal of less than 1:100, by comparing the likelihood of each SNP from the association analysis with the one

of the most strongly associated SNP⁴⁶. The remaining variants were then analysed using pupasuite 3.1 to identify potentially functional variants (Supplementary Table 9).

Functional analysis

Expression quantitative trait locus (eQTL) analysis in normal OSE and FTSE cells—Early-passage primary normal ovarian surface epithelial cells (OSECs) and fallopian tube epithelial cells were harvested from disease-free ovaries and fallopian tubes. Normal ovarian epithelial cells were collected by brushing the surface of the ovary with a sterile cytobrush, and were cultured in NOSE-CM⁵⁵. Fallopian tube epithelial cells were harvested by Pronase digestion as previously described⁵⁶, plated onto collagen-coated plastics (Sigma) and cultured in DMEM/F12 (Sigma-Aldrich) supplemented with 2% Ultrosor G (BioSeptra) and 1× penicillin/streptomycin (Lonza). By the time of RNA harvesting, fallopian tube cultures tested consisted of PAX8 positive fallopian tube secretory epithelial cells (FTSECs), consistent with previous observations that ciliated epithelial cells from the fallopian tube do not proliferate *in vitro*.

For gene expression analysis, RNA was harvested from 59 early passage samples: 54 OSECs and 5 FTSECs from cell cultures harvested at ~80% confluency using the QIAgen miRNAeasy kit with on-column DNase 1 digestion. 500ng RNA was reverse transcribed using the Superscript III kit (Life Technologies). We preamplified 10ng cDNA using the TaqMan[®] Preamp Mastermix; the resulting product was diluted 1:60 and used to quantify gene expression using the following TaqMan[®] gene expression probes: WNT4, Hs01573504_m1; RSP01, Hs00543475_m1; SYNPO2, Hs00326493_m1; ATAD5, Hs00227495_m1 and GPX6, Hs00699698_m1. Four control genes were also included: ACTB, Hs00357333_g1; GAPDH, Hs02758991_g1; HMBS, Hs00609293_g1 and HPRT1 Hs02800695_m1 (all Life Technologies). Assays were run on an ABI 7900HT Fast Real-Time PCR system (Life Technologies).

Data Analysis: Expression levels for each gene were normalized to the average of all four control genes. Relative expression levels were calculated using the $\delta\delta\text{Ct}$ method. Genotyping was performed on the iCOGs chips, as described above. Where genotyping data were not available for the most risk-associated SNP, the next most significant SNP was used: rs3820282 at 1p36, rs12023270 at 1p34.3, rs752097 at 4q26, rs445870 at 6p22.1, rs505922 at 9q34.2 and rs3764419 at 17q11.2. Correlations between genotype and gene expression were calculated in 'R'. Genotype specific gene expression in the normal tissue cell lines (eQTL analysis) was compared using the Jonckheere-Terpstra test. IData were normalized to the four control genes and we tested for eQTL associations, grouping OSECs and FTSECs together. Secondly, OSECs were analysed alone. eQTL analyses were performed using 3 genotype groups, or two groups (with the rare homozygote samples grouped together with the heterozygote samples).

eQTL analysis in primary ovarian tumours—eQTL analysis in primary tumours was based on the publicly available data available from The Cancer Genome Atlas (TCGA) project, which includes 489 primary high grade serous ovarian cancers. The methods have been described elsewhere⁵⁷. Briefly, we determined the ancestry for each case based on the

germ line genotype data using EIGENSTRAT software with 415 HapMap genotype profiles as a control set. Only populations of Northern and Western European ancestries were included. We first performed a *cis*-eQTL analyses using a method we described previously, in which the association between 906,600 germline genotypes and the expression levels of mRNA or miRNA (located within 500Kb on either side of the variant) were evaluated using linear regression model with the effects of somatic copy number and CpG methylation being deducted (For miRNA expression, the effect of CpG methylation is not adjusted for since the data are not available). To adjust for multiple tests, we adjusted the test P values using Benjamini-Hochberg method. A significant association was defined by a false discovery rate (FDR) of less than 0.1.

Having established a genome-wide *cis*-eQTL associations in this series of tumours, we then evaluated *cis*-eQTL associations for the top risk associations between each of the six new loci and the gene in closest proximity to the risk SNP. For each risk locus, we retrieved the genotype of all SNPs in ovarian cancer cases based on the Affymetrix 6.0 array. Using these genotypes and the impute2 March 2012 1000 Genomes Phase I integrated variant cosmopolitan reference panel of 1,092 individuals (Haplotypes were phased via SHAPEIT), we imputed the genotypes of SNPs in the 1000 Genomes Project in the target regions for TCGA samples⁵⁸. For each risk locus where data for the most risk-associated variant were not available, we retrieved the imputed variants tightly correlated with the most risk-associated variant. We then tested for association between imputed SNPs and gene expression using the linear regression algorithm described above, where each imputed SNP was coded as an expected allele count. Again, significant associations are defined by a false discovery rate (FDR) of less than 0.1.

Regulatory profiling of normal ovarian cancer precursor tissues—We performed genome-wide formaldehyde assisted regulatory element (FAIRE) and ChIP seq with histone 3 lysine 27 acetylation (H3K27ac) and histone 3 lysine 4 monomethylation (H3K4me) for two normal OSECs, two normal FTSECs and two HGSOc cell lines (UWB1.289 and CAOv3) [Shen et al. in preparation]. These datasets annotate epigenetic signatures of open chromatin, and collectively indicate transcriptional enhancer regions. We analysed the FAIRE-seq and ChIP-seq datasets and publically available genomic data on promoter and UTR domains, intron/exon boundaries, and positions of non-coding RNA transcripts to identify SNPs from the 100:1 likely causal set that align with biofeatures that may provide evidence of SNP functionality.

Candidate Gene Analysis Using Genome Wide Profiling of Primary Ovarian Cancers

Data Sets: The Cancer Genome Atlas (TCGA) Project and COSMIC Datasets

TCGA has performed extensive genomic analysis of tumours from a large number of tissue types including almost 500 high-grade serous ovarian tumours. These data include somatic mutations, DNA copy number, mRNA and miRNA expression and DNA methylation. COSMIC is the catalogue of somatic mutations in cancer that collates information on mutations in tumours from the published literature⁵⁹. They have also identified The Cancer

Gene Census, which is a list of genes known to be involved in cancer. Data are available on a large number of tissue types, including 2,809 epithelial ovarian tumours.

Somatic coding sequence mutations: We analysed all genes for coding somatic sequence mutations generated from either whole exome or whole genome sequencing. In TCGA, whole exome sequencing data were available for 316 high-grade serous EOC cases. In addition, we determined whether mutations had been reported in COSMIC⁵⁹ and whether the gene was a known cancer gene in the Sanger Cancer Gene Census.

mRNA expression in tumour and normal tissue: Normalized and gene expression values (Level 3) gene expression profiling data were obtained from the TCGA data portal for three different platforms (Agilent, Affymetrix HuEx and Affymetrix U133A). We analysed only the 489 primary serous ovarian tumour samples included in the final clustering analysis⁵⁸ and eight normal fallopian tube samples. The boxplot function in R was used to compare ovarian tumour samples to the fallopian tube for 91 coding genes with expression data on any platform within a 1MB region around the most significant SNP at the six loci. A difference in relative expression between EOC and normal tissue was carried out using the Wilcoxon rank-sum test.

DNA copy number analysis: Serous EOC samples for 481 tumours with log₂ copy number data were analysed using the cBio portal for analysis of TCGA data^{60,61}. For each gene in a region the classes of copy number; homozygous deletion, heterozygous loss, diploid, gain, and amplification were queried individually using the advanced onco query language (OQL) option. The frequency of gain and amplification were combined as “gain”, and homozygous deletion and heterozygous loss were combined as “loss”.

Analysis of copy number vs mRNA expression: Serous EOC samples for 316 complete tumours (those with CNA, mRNA and sequencing data) were analysed. Graphs were generated using the cBio portal for analysis of TCGA data and the setting were mRNA expression data Z-score (all genes) with the Z-score threshold of 2 (default setting) and putative copy number alterations (GISTIC). The Z-score is the number of standard deviations away from the mean of expression in the reference population. GISTIC is an algorithm that attempts to identify significantly altered regions of amplification or deletion across sets of patients.

Luciferase Reporter Assay—The putative causal SNPs at the 1p36 locus lie in the *WNT4* promoter and so we tested their effect on transcription in a luciferase reporter assay (Fig. 2D). Wild-type and risk haplotype (comprising five correlated variants) sequences corresponding to the region bound by hg19 co-ordinates chr1:22469416-22470869 were generated by Custom Gene Synthesis (GenScript Corporation), and then sub-cloned into pGL3-basic (Promega). Equimolar amounts of luciferase constructs (800 ng) and pRL-TK Renilla (50 ng) were co-transfected into $\sim 8 \times 10^4$ iOSE4⁶² normal ovarian cells in triplicate wells of 24 well plates using LipoFectamine 2000 (Life Technologies). Independent transfections were repeated three times. The Dual-Glo Luciferase Assay kit (Promega) was used to assay luciferase activity 24 hours post transfection using a BioTek Synergy H4 plate

reader. The iOSE-4 cell line (derived by K. Lawrenson) was maintained under standard conditions and routinely tested for *Mycoplasma* and short tandem repeat profiled.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Authors

Karoline B. Kuchenbaecker¹, Susan J. Ramus², Jonathan Tyrer³, Andrew Lee¹, Howard C. Shen², Jonathan Beesley⁴, Kate Lawrenson², Lesley McGuffog¹, Sue Healey⁴, Janet M. Lee², Tassja J. Spindler², Yvonne G. Lin⁵, Tanja Pejovic^{6,7}, Yukie Bean^{6,7}, Qiyuan Li⁸, Simon Coetzee^{9,10,11}, Dennis Hazelett^{12,13}, Alexander Miron¹⁴, Melissa Southey¹⁵, Mary Beth Terry¹⁶, David E. Goldgar¹⁷, Sandra S. Buys¹⁸, Ramunas Janavicius^{19,20}, Cecilia M. Dorfling²¹, Elizabeth J. van Rensburg²¹, Susan L. Neuhausen²², Yuan Chun Ding²², Thomas V. O. Hansen²³, Lars Jønson²³, Anne-Marie Gerdes²⁴, Bent Ejlersen²⁵, Daniel Barrowdale¹, Joe Dennis^{1,3}, Javier Benitez^{26,27,28}, Ana Osorio^{26,28}, Maria Jose Garcia^{26,28}, Ian Komenaka²⁹, Jeffrey N. Weitzel³⁰, Pamela Ganschow³¹, Paolo Peterlongo³², Loris Bernard^{33,34}, Alessandra Viel³⁵, Bernardo Bonanni³⁶, Bernard Peissel³⁷, Siranoush Manoukian³⁷, Paolo Radice³⁸, Laura Papi³⁹, Laura Ottini⁴⁰, Florentia Fostira⁴¹, Irene Konstantopoulou⁴¹, Judy Garber⁴², Debra Frost¹, Jo Perkins¹, Radka Platte¹, Steve Ellis¹, EMBRACE⁴³, Andrew K. Godwin⁴⁴, Rita Katharina Schmutzler^{45,46,47,48}, Alfons Meindl⁴⁹, Christoph Engel⁵⁰, Christian Sutter⁵¹, Olga M. Sinilnikova^{52,53}, GEMO Study Collaborators⁴³, Francesca Damiola⁵², Sylvie Mazoyer⁵², Dominique Stoppa-Lyonnet^{54,55,56}, Kathleen Claes⁵⁷, Kim De Leeneer⁵⁷, Judy Kirk⁵⁸, Gustavo C. Rodriguez⁵⁹, Marion Piedmonte⁶⁰, David M. O'Malley⁶¹, Miguel de la Hoya⁶², Trinidad Caldes⁶², Kristiina Aittomäki⁶³, Heli Nevanlinna⁶⁴, J. Margriet Collée⁶⁵, Matti A. Rookus⁶⁶, Jan C. Oosterwijk⁶⁷, Breast Cancer Family Registry⁴³, Laima Tihomirova⁶⁸, Nadine Tung⁶⁹, Ute Hamann⁷⁰, Claudine Isaacs⁷¹, Marc Tischkowitz⁷², Evgeny N. Imyanitov⁷³, Maria A. Caligo⁷⁴, Ian Campbell⁷⁵, Frans B.L. Hogervorst⁷⁶, HEBON⁴³, Edith Olah⁷⁷, Orland Diez⁷⁸, Ignacio Blanco⁷⁹, Joan Brunet⁸⁰, Conxi Lazaro⁸¹, Miquel Angel Pujana⁸², Anna Jakubowska⁸³, Jacek Gronwald⁸³, Jan Lubinski⁸³, Grzegorz Sukiennicki⁸³, Rosa B. Barkardottir⁸⁴, Marie Plante⁸⁵, Jacques Simard⁸⁶, Penny Soucy⁸⁶, Marco Montagna⁸⁷, Silvia Tognazzo⁸⁷, Manuel R. Teixeira^{88,89}, KConFab Investigators⁴³, Vernon S. Pankratz⁹⁰, Xianshu Wang⁹¹, Noralane Lindor⁹⁰, Csilla I. Szabo⁹², Noah Kauff⁹³, Joseph Vijai⁹³, Carol A. Aghajanian⁹³, Georg Pfeiler⁹⁴, Andreas Berger⁹⁴, Christian F. Singer⁹⁴, Muy-Kheng Tea⁹⁴, Catherine M. Phelan⁹⁵, Mark H. Greene⁹⁶, Phuong L. Mai⁹⁶, Gad Rennert⁹⁷, Anna Marie Mulligan^{98,99}, Sandrine Tchatchou¹⁰⁰, Irene L. Andrulis^{98,101}, Gord Glendon¹⁰⁰, Amanda Ewart Toland¹⁰², Uffe Birk Jensen¹⁰³, Torben A. Kruse¹⁰⁴, Mads Thomassen¹⁰⁴, Anders Bojesen¹⁰⁵, Jamal Zidan¹⁰⁶, Eitan Friedman¹⁰⁷, Yael Laitman¹⁰⁷, Maria Soller¹⁰⁸, Annelie Liljegren¹⁰⁹, Brita Arver¹⁰⁹, Zakaria Einbeigi¹¹⁰, Marie Stenmark-Askmal¹¹¹, Olufunmilayo I. Olopade¹¹², Robert L. Nussbaum¹¹³, Timothy R. Rebbeck¹¹⁴, Katherine L. Nathanson¹¹⁴, Susan M. Domchek¹¹⁴, Karen H. Lu¹¹⁵, Beth Y.

Karlan¹¹⁶, Christine Walsh¹¹⁶, Jenny Lester¹¹⁶, Australian Cancer Study (Ovarian Cancer Investigators)⁴³, Australian Ovarian Cancer Study Group⁴³, Alexander Hein¹¹⁷, Arif B. Ekici¹¹⁸, Matthias W. Beckmann¹¹⁷, Peter A. Fasching^{117,119}, Diether Lambrechts^{120,121}, Els Van Nieuwenhuysen¹²², Ignace Vergote¹²², Sandrina Lambrechts¹²², Ed Dicks³, Jennifer A. Doherty¹²³, Kristine G. Wicklund¹²⁴, Mary Anne Rossing^{124,125}, Anja Rudolph¹²⁶, Jenny Chang-Claude¹²⁶, Shan Wang-Gohrke¹²⁷, Ursula Eilber¹²⁶, Kirsten B. Moysich¹²⁸, Kunle Odunsi¹²⁹, Lara Sucheston-Campbell¹²⁸, Shashi Lele¹²⁸, Lynne R. Wilkens¹³⁰, Marc T. Goodman^{131,132}, Pamela J. Thompson^{131,132}, Yurii B. Shvetsov¹³⁰, Ingo B. Runnebaum¹³³, Matthias Dürst¹³³, Peter Hillemanns¹³⁴, Thilo Dörk¹³⁵, Natalia Antonenkova¹³⁶, Natalia Bogdanova¹³⁵, Arto Leminien⁶⁴, Liisa M. Peltari⁶⁴, Ralf Butzow^{64,137}, Francesmary Modugno^{138,139,140,141}, Joseph L. Kelley¹³⁹, Robert P. Edwards^{139,140}, Roberta B. Ness¹⁴², Andreas du Bois^{143,144}, Florian Heitz^{143,144}, Ira Schwaab¹⁴⁵, Philipp Harter^{143,144}, Keitaro Matsuo¹⁴⁶, Satoyo Hosono¹⁴⁷, Sandra Orsulic¹¹⁶, Allan Jensen¹⁴⁸, Susanne Kruger Kjaer^{148,149}, Estrid Hogdall^{148,150}, Hanis Nazihah Hasmad¹⁵¹, Mat Adenan Noor Azmi¹⁵², Soo-Hwang Teo^{151,153}, Yin-Ling Woo^{152,153}, Brooke L. Fridley¹⁵⁴, Ellen L. Goode⁹⁰, Julie M. Cunningham⁹¹, Robert A. Vierkant¹⁵⁵, Fiona Bruinsma¹⁵⁶, Graham G. Giles¹⁵⁶, Dong Liang¹⁵⁷, Michelle A.T. Hildebrandt¹⁵⁸, Xifeng Wu¹⁵⁸, Douglas A. Levine¹⁵⁹, Maria Bisogna¹⁵⁹, Andrew Berchuck¹⁶⁰, Edwin S. Iversen¹⁶¹, Joellen M. Schildkraut^{162,163}, Patrick Concannon^{164,165}, Rachel Palmieri Weber¹⁶³, Daniel W. Cramer^{166,167}, Kathryn L. Terry^{166,167}, Elizabeth M. Poole^{168,169}, Shelley S. Tworoger^{168,169}, Elisa V. Bandera¹⁷⁰, Irene Orlow¹⁷¹, Sara H. Olson¹⁷¹, Camilla Krakstad^{172,173}, Helga B. Salvesen^{172,173}, Ingvild L. Tangen^{172,173}, Line Bjorge^{172,173}, Anne M. van Altena¹⁷⁴, Katja K.H. Aben^{175,176}, Lambertus A. Kiemeny^{176,177}, Leon F.A.G. Massuger¹⁷⁴, Melissa Kellar^{6,7}, Angela Brooks-Wilson^{178,179}, Linda E. Kelemen¹⁸⁰, Linda S. Cook¹⁸¹, Nhu D. Le¹⁸², Cezary Cybulski¹⁸³, Hannah Yang¹⁸⁴, Jolanta Lissowska¹⁸⁵, Louise A. Brinton¹⁸⁴, Nicolas Wentzensen¹⁸⁴, Claus Hogdall¹⁴⁹, Lene Lundvall¹⁴⁹, Lotte Nedergaard¹⁸⁶, Helen Baker³, Honglin Song³, Diana Eccles¹⁸⁷, Ian McNeish¹⁸⁸, James Paul¹⁸⁹, Karen Carty¹⁸⁹, Nadeem Siddiqui¹⁹⁰, Rosalind Glasspool¹⁸⁹, Alice S. Whittemore¹⁹¹, Joseph H. Rothstein¹⁹¹, Valerie McGuire¹⁹¹, Weiva Sieh¹⁹¹, Bu-Tian Ji¹⁸⁴, Wei Zheng¹⁹², Xiao-Ou Shu¹⁹², Yu-Tang Gao¹⁹³, Barry Rosen^{194,195}, Harvey A. Risch¹⁹⁶, John R. McLaughlin¹⁹⁷, Steven A. Narod¹⁹⁸, Alvaro N. Monteiro⁹⁵, Ann Chen¹⁹⁹, Hui-Yi Lin¹⁹⁹, Jenny Permuth-Wey⁹⁵, Thomas A. Sellers⁹⁵, Ya-Yu Tsai⁹⁵, Zhihua Chen¹⁹⁹, Argyrios Ziogas²⁰⁰, Hoda Anton-Culver²⁰⁰, Aleksandra Gentry-Maharaj²⁰¹, Usha Menon²⁰¹, Patricia Harrington³, Alice W. Lee², Anna H. Wu², Celeste L. Pearce², Gerhard A. Coetzee^{12,13}, Malcolm C. Pike^{2,202}, Agnieszka Dansonka-Mieszkowska²⁰³, Agnieszka Timorek²⁰⁴, Iwona K. Rzepecka²⁰³, Jolanta Kupryjanczyk²⁰³, Matt Freedman⁸, Houtan Noushmehr^{9,10,11}, Douglas F. Easton¹, Kenneth Offit⁹³, Fergus J. Couch^{90,91}, Simon Gayther², Paul P. Pharoah³, Antonis C. Antoniou¹, Georgia Chenevix-Trench⁴, and on behalf of the Consortium of Investigators of Modifiers of *BRCA1* and *BRCA2*

Affiliations

¹Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK ²Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA ³Department of Oncology, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK ⁴Cancer Division, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia ⁵Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA ⁶Department of Obstetrics and Gynecology, Oregon Health and Science University, Portland, OR, USA ⁷Knight Cancer Institute, Portland, OR, USA ⁸Department of Medical Oncology, The Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA ⁹Department of Genetics, Ribeirão Preto Medical School, University of São Paulo, Brazil ¹⁰Center For Cell Based Therapy, Monte Alegre, Ribeirão Preto, SP, Brazil ¹¹Center for Integrative Systems Biology, Monte Alegre, Ribeirão Preto, SP, Brazil ¹²Department of Preventive Medicine, University of Southern California, Los Angeles, CA, USA ¹³Department of Urology, University of Southern California, Los Angeles, CA, USA ¹⁴Department of Genomics and Genome Sciences, Case Western Reserve University Medical School, Cleveland, OH, USA ¹⁵Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne, Parkville, VIC, Australia ¹⁶Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA ¹⁷Department of Dermatology, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, USA ¹⁸Department of Medicine, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, USA ¹⁹Vilnius University Hospital Santariskiu Clinics, Hematology, Oncology and Transfusion Medicine Center, Department of Molecular and Regenerative Medicine, Vilnius, Lithuania ²⁰State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania ²¹Department of Genetics, University of Pretoria, Pretoria, South Africa ²²Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, CA, USA ²³Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark ²⁴Department of Clinical Genetics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark ²⁵Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark ²⁶Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Centre (CNIO), Madrid, Spain ²⁷Genotyping Unit (CeGen), Human Cancer Genetics Program, Spanish National Cancer Centre (CNIO), Madrid, Spain ²⁸Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain ²⁹Maricopa Medical Center, care of City of Hope Clinical Cancer Genetics Community Research Network, Duarte, CA, USA ³⁰Clinical Cancer Genetics, for the City of Hope Clinical Cancer Genetics Community Research Network, Duarte, CA, USA ³¹Cook County Health and Hospital System, care of City of Hope Clinical Cancer Genetics Community Research Network, Duarte, CA, USA ³²IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Milan, Italy ³³Department of Experimental Oncology, Istituto Europeo di Oncologia, Milan, Italy

³⁴Cogentech Cancer Genetic Test Laboratory, Milan, Italy ³⁵Division of Experimental Oncology, CRO Aviano National Cancer Institute, Aviano (PN), Italy ³⁶Division of Cancer Prevention and Genetics, Istituto Europeo di Oncologia, Milan, Italy ³⁷Unit of Medical Genetics, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale Tumori (INT), Milan, Italy ³⁸Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale Tumori (INT), Milan, Italy ³⁹Unit of Medical Genetics, Department of Biomedical, Experimental and Clinical Sciences, University of Florence, Florence, Italy ⁴⁰Department of Molecular Medicine, University La Sapienza, Rome, Italy ⁴¹Molecular Diagnostics Laboratory, INRASTES, National Centre for Scientific Research "Demokritos", Aghia Paraskevi Attikis, Athens, Greece ⁴²Cancer Risk and Prevention Clinic, Dana Farber Cancer Institute, Boston, MA, USA ⁴⁴Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USA ⁴⁵Center for Hereditary Breast and Ovarian Cancer, Medical Faculty, University Hospital Cologne, Germany ⁴⁶Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Germany ⁴⁷Center for Molecular Medicine Cologne (CMMC), University of Cologne, Germany ⁴⁹Department of Gynaecology and Obstetrics, Division of Tumor Genetics, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany ⁵⁰Institute for Medical Informatics, Statistics and Epidemiology University of Leipzig, Leipzig, Germany ⁵¹University Heidelberg, Heidelberg, Germany ⁵²INSERM U1052, CNRS UMR5286, Université Lyon, Centre de Recherche en Cancérologie de Lyon, Lyon, France ⁵³Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon – Centre Léon Bérard, Lyon, France ⁵⁴Institut Curie, Department of Tumour Biology, Paris, France ⁵⁵Institut Curie, INSERM U830, Paris, France ⁵⁶Université Paris Descartes, Sorbonne Paris Cité, France ⁵⁷Center for Medical Genetics, Ghent University, Ghent, Belgium ⁵⁸Australia New Zealand Gynecologic Oncology Group (ANZGOG) and Familial Cancer Service, Westmead Hospital, Sydney, Australia ⁵⁹Division of Gynecologic Oncology, NorthShore University HealthSystem, Evanston, IL, USA ⁶⁰Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, NY, USA ⁶¹James Cancer Center, Ohio State University, Columbus, OH, USA ⁶²Molecular Oncology Laboratory, Hospital Clinico San Carlos, IdISSC, Madrid, Spain ⁶³Department of Clinical Genetics, Helsinki University Central Hospital, Helsinki, Finland ⁶⁴Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Central Hospital, Helsinki, HUS, Finland ⁶⁵Department of Clinical Genetics, Family Cancer Clinic, Erasmus University Medical Center, Rotterdam, The Netherlands ⁶⁶Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands ⁶⁷Department of Genetics, University Medical Center, Groningen University, Groningen, The Netherlands ⁶⁸Latvian Biomedical Research and Study Centre, Riga, Latvia ⁶⁹Department of Medical Oncology, Beth Israel Deaconess Medical Center ⁷⁰Molecular Genetics of Breast Cancer, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany ⁷¹Lombardi Comprehensive Cancer Center, Georgetown University, Washington

DC, USA ⁷²Program in Cancer Genetics, McGill University, Montreal, Quebec, Canada ⁷³N.N. Petrov Institute of Oncology, St.Petersburg, Russia ⁷⁴Section of Genetic Oncology, Department of Laboratory Medicine, University and University Hospital of Pisa, Pisa, Italy ⁷⁵VBCRC Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia ⁷⁶Family Cancer Clinic, Netherlands Cancer Institute, Amsterdam, The Netherlands ⁷⁷Department of Molecular Genetics, National Institute of Oncology, Budapest, Hungary ⁷⁸Oncogenetics Group, University Hospital Vall d'Hebron, Vall d'Hebron Institute of Oncology (VHIO) and Universitat Autònoma de Barcelona; Barcelona, Spain ⁷⁹Genetic Counseling Unit, Hereditary Cancer Program, IDIBELL-Catalan Institute of Oncology, Barcelona, Spain ⁸⁰Genetic Counseling Unit, Hereditary Cancer Program, IDIBGI-Catalan Institute of Oncology, Girona, Spain ⁸¹Molecular Diagnostic Unit, Hereditary Cancer Program, IDIBELL-Catalan Institute of Oncology, Barcelona, Spain ⁸²Breast Cancer and Systems Biology Unit, IDIBELL-Catalan Institute of Oncology, Barcelona, Spain ⁸³Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland ⁸⁴Department of Pathology, Landspítali University Hospital and BMC, Faculty of Medicine, University of Iceland, Reykjavik, Iceland ⁸⁵Gynaecologic Oncology Service, Centre Hospitalier Universitaire de Québec (CHUQ), Québec, Canada ⁸⁶Centre Hospitalier Universitaire de Québec Research Center, Laval University, Quebec City, Canada ⁸⁷Immunology and Molecular Oncology Unit, Istituto Oncologico Veneto IOV - IRCCS, Padua, Italy ⁸⁸Biomedical Sciences Institute (ICBAS), Porto University, Porto, Portugal ⁸⁹Department of Genetics, Portuguese Oncology Institute, Porto, Portugal ⁹⁰Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA ⁹¹Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA ⁹²National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA ⁹³Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, USA ⁹⁴Department of Obstetrics and Gynecology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria ⁹⁵Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA ⁹⁶Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA ⁹⁷Department of Community Medicine and Epidemiology, Carmel Medical Center, Haifa, Israel ⁹⁸Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada ⁹⁹Laboratory Medicine Program, University Health Network, Toronto, ON, Canada ¹⁰⁰Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, ON, Canada ¹⁰¹Department of Molecular Genetics, University of Toronto, ON, Canada ¹⁰²Department of Molecular Virology, Immunology and Medical Genetics, Columbus, OH, USA ¹⁰³Department of Clinical Genetics, Aarhus University Hospital, Aarhus N, Denmark ¹⁰⁴Department of Clinical Genetics, Odense University Hospital, Odense C, Denmark ¹⁰⁵Department of Clinical Genetics, Vejle Hospital, Vejle, Denmark ¹⁰⁶Institute of Oncology, Rivka Ziv Medical Center, Zefat, Israel ¹⁰⁷Susanne Levy Gertner Oncogenetics Unit, Sheba Medical Center, Tel Aviv, Israel ¹⁰⁸Department of Clinical Genetics, Lund University Hospital, Lund, Sweden

¹⁰⁹Department of Oncology, Karolinska University Hospital, Stockholm, Sweden
¹¹⁰Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden
¹¹¹Division of Clinical Genetics, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden ¹¹²Center for Clinical Cancer Genetics and Global Health, University of Chicago Medical Center, Chicago, USA ¹¹³Department of Medicine and Genetics, University of California, San Francisco, USA
¹¹⁴Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, PA, USA ¹¹⁵Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA ¹¹⁶Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA ¹¹⁷Department of Obstetrics and Gynecology, Erlangen University Hospital, University of Erlangen-Nuremberg, Erlangen, Germany ¹¹⁸Institute of Human Genetics, University of Erlangen-Nuremberg, Erlangen, Germany ¹¹⁹University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, Los Angeles, CA, USA ¹²⁰Vesalius Research Center, VIB, Leuven, Belgium ¹²¹Laboratory for Translational Genetics, Department of Oncology, University of Leuven, Belgium ¹²²Division of Gynecological Oncology, Department of Oncology, University Hospitals Leuven, Belgium ¹²³Department of Community and Family Medicine, Section of Biostatistics & Epidemiology, The Geisel School of Medicine at Dartmouth, Lebanon, NH, USA ¹²⁴Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA ¹²⁵Department of Epidemiology, University of Washington, Seattle, WA, USA
¹²⁶German Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Heidelberg, Germany ¹²⁷Department of Obstetrics and Gynecology, University of Ulm, Ulm, Germany ¹²⁸Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA ¹²⁹Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA ¹³⁰Cancer Epidemiology Program, University of Hawaii Cancer Center, Hawaii, USA ¹³¹Cancer Prevention and Control, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA ¹³²Community and Population Health Research Institute, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA ¹³³Department of Gynecology, Jena University Hospital - Friedrich Schiller University, Jena, Germany ¹³⁴Clinics of Obstetrics and Gynaecology, Hannover Medical School, Hannover, Germany ¹³⁵Gynaecology Research Unit, Hannover Medical School, Hannover, Germany ¹³⁶Byelorussian Institute for Oncology and Medical Radiology Aleksandrov N.N., Minsk, Belarus ¹³⁷Department of Pathology, Helsinki University Central Hospital, Helsinki, Finland ¹³⁸Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA ¹³⁹Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
¹⁴⁰Ovarian Cancer Center of Excellence, University of Pittsburgh, Pittsburgh, PA, USA ¹⁴¹Women's Cancer Research Program, Magee-Women's Research Institute and University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA ¹⁴²The University

of Texas School of Public Health, Houston, TX, USA ¹⁴³Department of Gynecology and Gynecologic Oncology, Dr. Horst Schmidt Kliniken Wiesbaden, Wiesbaden, Germany ¹⁴⁴Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte, Essen, Germany ¹⁴⁵Institut für Humangenetik Wiesbaden, Wiesbaden, Germany ¹⁴⁶Department of Preventive Medicine, Kyushu University Faculty of Medical Sciences, Fukuoka, Fukuoka, Japan ¹⁴⁷Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan ¹⁴⁸Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark ¹⁴⁹Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark ¹⁵⁰Molecular Unit, Department of Pathology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark ¹⁵¹Cancer Research Initiatives Foundation, Sime Darby Medical Centre, Subang Jaya, Malaysia ¹⁵²Department of Obstetrics and Gynaecology, University Malaya Medical Centre, University Malaya, Kuala Lumpur, Malaysia ¹⁵³University Malaya Cancer Research Institute, Faculty of Medicine, University Malaya Medical Centre, University Malaya, Kuala Lumpur, Malaysia ¹⁵⁴Biostatistics and Informatics Shared Resource, University of Kansas Medical Center, Kansas City, KS, USA ¹⁵⁵Department of Health Science Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA ¹⁵⁶Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, VIC, Australia ¹⁵⁷College of Pharmacy and Health Sciences, Texas Southern University, Houston, Texas, USA ¹⁵⁸Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA ¹⁵⁹Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA ¹⁶⁰Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC, USA ¹⁶¹Department of Statistical Science, Duke University, Durham, North Carolina, USA ¹⁶²Cancer Control and Population Sciences, Duke Cancer Institute, Durham, North Carolina, USA ¹⁶³Department of Community and Family Medicine, Duke University Medical Center, Durham, NC, USA ¹⁶⁴Department of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, FL, USA ¹⁶⁵Genetics Institute, University of Florida, Gainesville, FL, USA ¹⁶⁶Harvard School of Public Health, Boston, MA, USA ¹⁶⁷Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA ¹⁶⁸Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA ¹⁶⁹Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA ¹⁷⁰Cancer Prevention and Control, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA ¹⁷¹Memorial Sloan Kettering Cancer Center, Department of Epidemiology and Biostatistics, Epidemiology Service, New York, NY, USA ¹⁷²Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Bergen, Norway ¹⁷³Department of Gynecology and Obstetrics, Haukeland University Hospital, Bergen, Norway ¹⁷⁴Department of Gynaecology, Radboud University Medical Centre, Nijmegen, The Netherlands ¹⁷⁵Comprehensive Cancer Center The Netherlands, Utrecht, The Netherlands ¹⁷⁶Department for Health Evidence, Radboud University Medical Centre, Nijmegen, The Netherlands

¹⁷⁷Department of Urology, Radboud University Medical Centre, Nijmegen, Netherlands ¹⁷⁸Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, BC, Canada ¹⁷⁹Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, BC Canada ¹⁸⁰Department of Public Health Sciences, College of Medicine, Medical University of South Carolina, Charleston, USA ¹⁸¹Division of Epidemiology and Biostatistics, Department of Internal Medicine, University of New Mexico, Albuquerque, NM, USA ¹⁸²Cancer Control Research, BC Cancer Agency, Vancouver, BC, Canada ¹⁸³International Hereditary Cancer Center, Department of Genetics and Pathology, Clinic of Ophthalmology, Pomeranian Medical University, Szczecin, Poland ¹⁸⁴Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA ¹⁸⁵Department of Cancer Epidemiology and Prevention, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland ¹⁸⁶Department of Pathology, Rigshospitalet, University of Copenhagen, Denmark ¹⁸⁷Wessex Clinical Genetics Service, Princess Anne Hospital, Southampton, UK ¹⁸⁸Institute of Cancer Sciences, University of Glasgow, Wolfson Wohl Cancer Research Centre, Beatson Institute for Cancer Research, Glasgow, UK ¹⁸⁹Cancer Research UK Clinical Trials Unit, Glasgow, The Beatson West of Scotland Cancer Centre, Glasgow, UK ¹⁹⁰Department of Gynaecological Oncology, Glasgow Royal Infirmary, Glasgow, UK ¹⁹¹Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, CA, USA ¹⁹²Vanderbilt University School of Medicine, Nashville, TN, USA ¹⁹³Shanghai Cancer Institute, Shanghai, China ¹⁹⁴Department of Obstetrics and Gynecology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada ¹⁹⁵Department of Gynecologic-Oncology, Princess Margaret Hospital, Toronto, ON, Canada ¹⁹⁶Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, USA ¹⁹⁷Prosserman Centre for Health Research, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada ¹⁹⁸Women's College Research Institute, University of Toronto, Toronto, ON, Canada ¹⁹⁹Department of Biostatistics, Moffitt Cancer Center, Tampa, FL, USA ²⁰⁰Department of Epidemiology, University of California Irvine, Irvine, CA, USA ²⁰¹Women's Cancer, UCL EGA Institute for Women's Health, London, UK ²⁰²Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA ²⁰³Department of Pathology, The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland ²⁰⁴Department of Obstetrics, Gynecology and Oncology, IInd Faculty of Medicine, Warsaw Medical University and Brodnowski Hospital, Warsaw, Poland

Acknowledgments

We thank all the individuals who took part in this study, and all the researchers, clinicians and technical and administrative staff who made possible the many studies contributing to this work (a full list is provided in the Supplementary Note), including Xiao Qing Chen for iPLEX genotyping. The COGS project is funded through a European Commission's Seventh Framework Programme grant (agreement number 223175 - HEALTH-F2-2009-223175). The CIMBA data management and data analysis were supported by Cancer Research-UK grants C12292/A11174 and C1287/A10118. The Ovarian Cancer Association Consortium is supported by a grant from the

Ovarian Cancer Research Fund thanks to donations by the family and friends of Kathryn Sladek Smith (PPD/RPCI. 07). The scientific development and funding for this project were in part supported by the US National Cancer Institute GAME-ON Post-GWAS Initiative (U19-CA148112). This study made use of data generated by the Wellcome Trust Case Control consortium. Funding for the project was provided by the Wellcome Trust under award 076113. The results published here are in part based upon data generated by The Cancer Genome Atlas Pilot Project established by the National Cancer Institute and National Human Genome Research Institute (dbGap accession number phs000178.v8.p7). The cBio portal is developed and maintained by the Computational Biology Center at Memorial Sloan-Kettering Cancer Center. SH is supported by an NHMRC Program Grant to GCT. Details of the funding of individual investigators and studies are provided in the Supplementary Note. This study made use of data generated by the Wellcome Trust Case Control consortium, funding for which was provided by the Wellcome Trust under award 076113. The results published here are, in part, based upon data generated by The Cancer Genome Atlas Pilot Project established by the National Cancer Institute and National Human Genome Research Institute (dbGap accession number phs000178.v8.p7). A full list of the investigators who contributed to the generation of the data is available on the website (see URL). The cBio portal was developed and is maintained by the Computational Biology Center at Memorial Sloan-Kettering Cancer Center.

REFERENCES

1. Auranen A, et al. Cancer incidence in the first-degree relatives of ovarian cancer patients. *Br J Cancer*. 1996; 74:280–284. [PubMed: 8688336]
2. Stratton JF, Pharoah P, Smith SK, Easton D, Ponder BA. A systematic review and meta-analysis of family history and risk of ovarian cancer. *Br J Obstet Gynaecol*. 1998; 105:493–499. [PubMed: 9637117]
3. Jervis S, et al. Ovarian cancer familial relative risks by tumour subtypes and by known ovarian cancer genetic susceptibility variants. *J Med Genet*. 2013
4. Bolton KL, et al. Common variants at 19p13 are associated with susceptibility to ovarian cancer. *Nat Genet*. 2010; 42:880–884. [PubMed: 20852633]
5. Goode EL, et al. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. *Nat Genet*. 2010; 42:874–879. [PubMed: 20852632]
6. Song H, et al. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. *Nat Genet*. 2009; 41:996–1000. [PubMed: 19648919]
7. Pharoah PD, et al. GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. *Nat Genet*. 2013; 45:362–370. 370e361–370e362. [PubMed: 23535730]
8. Permut-Wey J, et al. Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. *Nat Commun*. 2013; 4:1627. [PubMed: 23535648]
9. Bojesen SE, et al. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. *Nat Genet*. 2013; 45:371–384. 384e371–384e372. [PubMed: 23535731]
10. Couch FJ, et al. Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiol Biomarkers Prev*. 2012; 21:645–657. [PubMed: 22351618]
11. Ramus SJ, et al. Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. *Hum Mutat*. 2012; 33:690–702. [PubMed: 22253144]
12. Ramus SJ, et al. Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. *J Natl Cancer Inst*. 2011; 103:105–116. [PubMed: 21169536]
13. Couch FJ, et al. Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. *PLoS Genet*. 2013; 9:e1003212. [PubMed: 23544013]
14. Bolton KL, Ganda C, Berchuck A, Pharoah PD, Gayther SA. Role of common genetic variants in ovarian cancer susceptibility and outcome: progress to date from the Ovarian Cancer Association Consortium (OCAC). *J Intern Med*. 2012; 271:366–378. [PubMed: 22443200]
15. Chenevix-Trench G, et al. An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA). *Breast Cancer Res*. 2007; 9:104. [PubMed: 17466083]
16. Gaudet MM, et al. Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. *PLoS Genet*. 2013; 9:e1003173. [PubMed: 23544012]

17. Genomes Project, C. An integrated map of genetic variation from 1,092 human genomes. *Nature*. 2012; 491:56–65. [PubMed: 23128226]
18. Barnes DR, et al. Evaluation of association methods for analysing modifiers of disease risk in carriers of high-risk mutations. *Genet Epidemiol*. 2012; 36:274–291. [PubMed: 22714938]
19. Bourguignon LY, Gilad E, Rothman K, Peyrollier K. Hyaluronan-CD44 interaction with IQGAP1 promotes Cdc42 and ERK signaling, leading to actin binding, Elk-1/estrogen receptor transcriptional activation, and ovarian cancer progression. *J Biol Chem*. 2005; 280:11961–11972. [PubMed: 15655247]
20. Zuo Y, Wu Y, Chakraborty C. Cdc42 negatively regulates intrinsic migration of highly aggressive breast cancer cells. *J Cell Physiol*. 2012; 227:1399–1407. [PubMed: 21618528]
21. Pagliardini L, et al. An Italian association study and meta-analysis with previous GWAS confirm WNT4, CDKN2BAS and FN1 as the first identified susceptibility loci for endometriosis. *J Med Genet*. 2013; 50:43–46. [PubMed: 23142796]
22. Pearce CL, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. *Lancet Oncol*. 2012; 13:385–394. [PubMed: 22361336]
23. Tomaselli S, et al. Human RSPO1/R-spondin1 is expressed during early ovary development and augments beta-catenin signaling. *PLoS One*. 2011; 6:e16366. [PubMed: 21297984]
24. Parma P, et al. R-spondin1 is essential in sex determination, skin differentiation and malignancy. *Nat Genet*. 2006; 38:1304–1309. [PubMed: 17041600]
25. Tomizuka K, et al. R-spondin1 plays an essential role in ovarian development through positively regulating Wnt-4 signaling. *Hum Mol Genet*. 2008; 17:1278–1291. [PubMed: 18250097]
26. De Ganck A, et al. Multiple isoforms of the tumor suppressor myopodin are simultaneously transcribed in cancer cells. *Biochem Biophys Res Commun*. 2008; 370:269–273. [PubMed: 18371299]
27. Jing L, et al. Expression of myopodin induces suppression of tumor growth and metastasis. *Am J Pathol*. 2004; 164:1799–1806. [PubMed: 15111326]
28. Lin F, et al. Myopodin, a synaptopodin homologue, is frequently deleted in invasive prostate cancers. *Am J Pathol*. 2001; 159:1603–1612. [PubMed: 11696420]
29. Sanchez-Carbayo M, Schwarz K, Charytonowicz E, Cordon-Cardo C, Mundel P. Tumor suppressor role for myopodin in bladder cancer: loss of nuclear expression of myopodin is cell-cycle dependent and predicts clinical outcome. *Oncogene*. 2003; 22:5298–5305. [PubMed: 12917631]
30. Yu YP, Luo JH. Myopodin-mediated suppression of prostate cancer cell migration involves interaction with zyxin. *Cancer Res*. 2006; 66:7414–7419. [PubMed: 16885336]
31. Amundadottir L, et al. Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. *Nat Genet*. 2009; 41:986–990. [PubMed: 19648918]
32. Rummel S, Shriver CD, Ellsworth RE. Relationships between the ABO blood group SNP rs505922 and breast cancer phenotypes: a genotype-phenotype correlation study. *BMC Med Genet*. 2012; 13:41. [PubMed: 22642827]
33. Poole EM, et al. ABO blood group and risk of epithelial ovarian cancer within the Ovarian Cancer Association Consortium. *Cancer Causes Control*. 2012; 23:1805–1810. [PubMed: 22961099]
34. Sikdar N, et al. DNA damage responses by human ELG1 in S phase are important to maintain genomic integrity. *Cell Cycle*. 2009; 8:3199–3207. [PubMed: 19755857]
35. Bell DW, et al. Predisposition to cancer caused by genetic and functional defects of mammalian Atad5. *PLoS Genet*. 2011; 7:e1002245. [PubMed: 21901109]
36. Lee KY, et al. Human ELG1 regulates the level of ubiquitinated proliferating cell nuclear antigen (PCNA) through its interactions with PCNA and USP1. *J Biol Chem*. 2010; 285:10362–10369. [PubMed: 20147293]
37. Wacholder S, Han SS, Weinberg CR. Inference from a multiplicative model of joint genetic effects for [corrected] ovarian cancer risk. *J Natl Cancer Inst*. 2011; 103:82–83. [PubMed: 21169538]
38. Hnisz D, et al. Super-enhancers in the control of cell identity and disease. *Cell*. 2013; 155:934–947. [PubMed: 24119843]

39. Permut-Wey J, et al. LIN28B polymorphisms influence susceptibility to epithelial ovarian cancer. *Cancer Res.* 2011; 71:3896–3903. [PubMed: 21482675]
40. GenABEL: genome-wide SNP association analysis. 2013
41. Delaneau O, Marchini J, Zagury JF. A linear complexity phasing method for thousands of genomes. *Nature Methods.* 2012; 9:179–181. doi: [PubMed: 22138821]
42. Howie BN, Donnelly P, Marchini J. A Flexible and Accurate Genotype Imputation Method for the Next Generation of Genome-Wide Association Studies. *Plos Genetics.* 2009; 5 doi:ARTN e1000529.
43. Antoniou AC, et al. RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. *Am J Hum Genet.* 2007; 81:1186–1200. [PubMed: 17999359]
44. Antoniou AC, et al. A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. *Nat Genet.* 2010; 42:885–892. [PubMed: 20852631]
45. R: A Language and Environment for Statistical Computing v. 3.0.1. Vienna, Austria: R Foundation for Statistical Computing; 2013.
46. Udler MS, Tyrer J, Easton DF. Evaluating the power to discriminate between highly correlated SNPs in genetic association studies. *Genet Epidemiol.* 2010; 34:463–468. [PubMed: 20583289]
47. Reumers J, et al. Joint annotation of coding and non-coding single nucleotide polymorphisms and mutations in the SNP effect and PupaSuite databases. *Nucleic Acids Res.* 2008; 36:D825–D829. [PubMed: 18086700]
48. Conde L, et al. PupaSuite: finding functional single nucleotide polymorphisms for large-scale genotyping purposes. *Nucleic Acids Res.* 2006; 34:W621–W625. [PubMed: 16845085]
49. Mavaddat N, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). *Cancer Epidemiol Biomarkers Prev.* 2012; 21:134–147. [PubMed: 22144499]
50. Lakhani SR, et al. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. *Clin Cancer Res.* 2004; 10:2473–2481. [PubMed: 15073127]
51. Rubin SC, et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. *N Engl J Med.* 1996; 335:1413–1416. [PubMed: 8875917]
52. Maehle L, et al. High risk for ovarian cancer in a prospective series is restricted to BRCA1/2 mutation carriers. *Clin Cancer Res.* 2008; 14:7569–7573. [PubMed: 19010876]
53. Shaw PA, et al. Histopathologic features of genetically determined ovarian cancer. *Int J Gynecol Pathol.* 2002; 21:407–411. [PubMed: 12352190]
54. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics.* 2010; 26:2190–2191. [PubMed: 20616382]
55. Li NF, et al. A modified medium that significantly improves the growth of human normal ovarian surface epithelial (OSE) cells in vitro. *Lab Invest.* 2004; 84:923–931. [PubMed: 15077121]
56. Fotheringham S, Levanon K, Drapkin R. Ex vivo culture of primary human fallopian tube epithelial cells. *J Vis Exp.* 2011
57. Li Q, et al. Expressopn QTL based analyses reveal candidate causal genes and loci across five tumor types. *Hum Mol Genet.* 2014 (**in press**).
58. Cancer Genome Atlas Research, N. Integrated genomic analyses of ovarian carcinoma. *Nature.* 2011; 474:609–615. [PubMed: 21720365]
59. Forbes SA, et al. The Catalogue of Somatic Mutations in Cancer (COSMIC). *Curr Protoc Hum Genet.* 2008; Chapter 10(Unit 10):11. [PubMed: 18428421]
60. Gao J, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Sci Signal.* 2013; 6:p11. [PubMed: 23550210]
61. Cerami E, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov.* 2012; 2:401–404. [PubMed: 22588877]
62. Lawrenson K, et al. Senescent fibroblasts promote neoplastic transformation of partially transformed ovarian epithelial cells in a three-dimensional model of early stage ovarian cancer. *Neoplasia.* 2010; 12:317–325. [PubMed: 20360942]




Figure 1. Hazard ratios for the association with EOC of 12 previously reported epithelial ovarian cancer susceptibility variants and the six novel susceptibility variants for OCAC, *BRCA1* mutation carriers and *BRCA2* mutation carriers




Figure 2.
 The 1p36 epithelial ovarian cancer susceptibility locus
 A) The Manhattan plot depicts the strength of association between all imputed and genotyped SNPs across the region bound by hg19 co-ordinates chr1:21922893-22991643. The dotted line represents the genome-wide significance level 5×10^{-8} . Additional tracks show genes and enhancers in ovary as described in Hnisz et al³⁸. Positions of SNPs for which imputation $r^2 < 0.3$ and/or minor allele frequency < 0.005 are shown in the bottom track as ‘untyped’ SNPs.
 B) The shaded iCHAV from (A) is shown depicting the genes and the location of the *WNT4* promoter construct as a red box. Red ticks show the positions of the putative causal variants following likelihood ratio testing. Signals from FAIRE-seq data derived from ovarian cells are represented by black marks, and the locations of predicted *CDC42* enhancers³⁸ as blue boxes. The positions of genotyped SNPs, and those that were neither genotyped nor well imputed (‘untyped’), are shown.

C) Normalised luciferase reporter activity following triplicate transfections of wildtype and risk haplotype *WNT4* promoter constructs in iOSE4 cells. Error bars represent standard error from three independent experiments.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 1

Association test results for loci associated at $p < 5 \times 10^{-8}$ in the second imputation stage. Results reported for ovarian cancer in *BRCA1* and *BRCA2* mutation carriers, ovarian cancer as well as serous subtype in OCAC, the meta-analysis for ovarian cancer, and for the meta-analysis for all tumour histologies in *BRCA1* and *BRCA2* and serous ovarian cancer in OCAC. SNP with smallest p-value reported for each locus

Locus	Nearest gene	rs#	Ref ⁶	Eff ⁶	EAF ⁷	OCAC all histologies			OCAC serous			<i>BRCA1</i> carriers			<i>BRCA2</i> carriers			MA all histologies ¹			MA serous ²		
						r ² *	OR (95%CI)	P	OR (95%CI)	P	OR (95%CI)	P	r ² *	HR (95%CI)	P	r ² *	HR (95%CI)	P	r ² *	HR (95%CI)	P	r ² *	HR (95%CI)
1p36	<i>WNT4</i>	rs56318008	C	T	0.15	0.98	1.11 (1.07–1.16)	3.9×10 ⁻⁷	1.12 (1.07–1.18)	3.1×10 ⁻⁶	0.98	1.15 (1.05–1.26)	3.1×10 ⁻³	0.98	1.03 (0.86–1.23)	0.74	7.6×10 ⁻⁹	5.7×10 ⁻⁸					
1p34.3	<i>RSPO1</i>	rs58722170	G	C	0.23	0.85	1.08 (1.04–1.12)	9.7×10 ⁻⁵	1.12 (1.08–1.18)	1.1×10 ⁻⁷	0.83	1.14 (1.05–1.23)	1.5×10 ⁻³	0.83	1.35 (1.17–1.57)	5.2×10 ⁻⁵	1.6×10 ⁻⁸	2.7×10 ⁻¹²					
4q26	<i>SYNP2</i>	rs17329882	A	C	0.24	0.95	1.09 (1.06–1.13)	5.9×10 ⁻⁷	1.11 (1.07–1.16)	6.4×10 ⁻⁷	0.93	1.08 (1.00–1.17)	0.042	0.93	1.15 (1.00–1.33)	0.06	1.4×10 ⁻⁸	1.6×10 ⁻⁸					
6p22.1	<i>GPX6</i>	rs116133110 ⁴	T	C	0.31	0.99	0.93 (0.91–0.97)	9.0×10 ⁻⁵	0.91 (0.87–0.94)	2.6×10 ⁻⁷	0.99	0.92 (0.86–0.99)	0.023	0.99	0.97 (0.85–1.10)	0.64	6.8×10 ⁻⁶	3.0×10 ⁻⁸					
9q34.2	<i>ABO</i>	rs635634	C	T	0.19	0.85	1.11 (1.07–1.16)	1.1×10 ⁻⁷	1.12 (1.08–1.18)	1.0×10 ⁻⁶	0.83	1.11 (1.02–1.21)	0.012	0.83	1.05 (0.89–1.23)	0.55	4.4×10 ⁻⁹	4.2×10 ⁻⁸					
17q11.2	<i>ATAD5</i>	chr17:29181220:1 ⁵	A	AT	0.28	0.95	0.91 (0.88–0.94)	5.4×10 ⁻⁹	0.91 (0.87–0.94)	8.1×10 ⁻⁷	0.94	1.01 (0.94–1.08)	0.88	0.93	0.92 (0.80–1.05)	0.23	2.6×10 ⁻⁹ * ³	3.9×10 ⁻⁷ * ³					

* Imputation accuracy r² estimate

¹ P-value from the meta-analysis association test for ovarian cancer in OCAC and *BRCA1* and *BRCA2* carriers

² P-value from the meta-analysis association test for ovarian cancer in *BRCA1* and *BRCA2* carriers and serous ovarian cancer in OCAC

³ meta-analysis of ovarian cancer associations in *BRCA2* carriers and OCAC only

⁴ rs116133110 listed as rs6456822 on dbSNP

⁵ chr17:29181220:1 listed as rs199661266 on dbSNP

⁶ Reference and effect allele

⁷ Effect allele frequency

Table 2

Associations with ovarian cancer subtypes in OCAC samples for loci associated with ovarian cancer at $p < 5 \times 10^{-8}$ in the meta-analysis

Locus	rs#	All histologies			Serous			Endometrioid			Clear cell			Mucinous			p-het*
		OR (95%CI)	P	OR (95%CI)	OR (95%CI)	P	OR (95%CI)	OR (95%CI)	P	OR (95%CI)	OR (95%CI)	P	OR (95%CI)	OR (95%CI)	P		
1p36	rs56318008	1.11 (1.06–1.15)	8×10^{-7}	1.12 (1.06–1.17)	6×10^{-6}	1.09 (1.00–1.19)	0.05	1.24 (1.10–1.39)	5×10^{-4}	1.03 (0.91–1.17)	0.65	0.22					
1p34.3	rs58722170	1.07 (1.03–1.11)	2×10^{-4}	1.12 (1.07–1.17)	4×10^{-7}	0.94 (0.87–1.02)	0.16	1.00 (0.89–1.12)	0.98	1.08 (0.97–1.21)	0.17	0.001					
4q26	rs17329882	1.09 (1.06–1.13)	3×10^{-7}	1.11 (1.07–1.16)	3×10^{-7}	1.09 (1.01–1.18)	0.020	1.06 (0.96–1.18)	0.26	1.11 (0.99–1.23)	0.06	0.88					
6p22.1	rs116133110	0.94 (0.91–0.97)	9×10^{-5}	0.91 (0.87–0.94)	3×10^{-7}	0.95 (0.89–1.02)	0.16	1.05 (0.95–1.15)	0.34	1.03 (0.94–1.14)	0.53	0.008					
9q34.2	rs635634	1.12 (1.08–1.16)	9×10^{-9}	1.13 (1.08–1.18)	2×10^{-7}	1.12 (1.03–1.21)	0.007	1.03 (0.92–1.16)	0.58	1.23 (1.10–1.38)	3×10^{-4}	0.23					
17q11.2	chr17:29181220:1	0.90 (0.87–0.93)	1×10^{-9}	0.90 (0.87–0.94)	2×10^{-7}	0.88 (0.82–0.95)	5×10^{-4}	0.88 (0.80–0.98)	0.020	1.01 (0.91–1.12)	0.84	0.18					

* p-value for the heterogeneity in associations with different tumour subtypes

Table 3

Summary of data on SNPs, closest gene and all genes in 1 MB region for each locus

Loci	Position of top SNP	# putatively causal SNPs	Genes in window of putatively causal SNPs	# SNPs aligned w/ biofeatures ^b	Normal eQTL closest gene	Tumour DNA copy number	Significant expression difference in tumour vs normal	Known role of gene in cancer	# Genes in IMB region	Other known cancer genes in IMB region
1p36	promoter region of <i>WNT4</i>	39	<i>WNT4, CDC42, LINC00339</i>	11	NS	loss		Yes	11	<i>RAP1GAP, CDC42</i>
1p34.3	intron 3 of <i>RSPO1</i>	15	<i>RSPO1</i>	0	NS	gain		Yes	22	<i>Clorf109, FHL3</i>
4q26	intron 3 of <i>SYNPO2</i>	4	<i>SYNPO2</i>	2	NS**	loss	down	Yes	12	none
6p22.1	intron 1 of <i>GPX6</i>	22	<i>GPX6, GPX5</i>	1	N/A	gain			23	<i>ZKSCAN3, TRIM27</i>
9q34.2	4.3kb upstream of <i>ABO</i>	18	<i>ABO, SLC2A6*</i>	1	NS	loss	down	Yes	32	<i>TSCI, RALGDS, RPL7A, VAV2</i>
17q11.2	intron 6 of <i>ATAD5</i>	16	<i>ATAD5, TEFM, ADAP2, CRLF3, SUZ12PI</i>	0	NS	loss	up	Yes	17	<i>NF1</i>

Proximal promoter regions were defined as 1kb upstream of the transcription start site
N/A, indicated no expression of *GPX6* in normal tissues. NS, not significant.

^b Biofeatures defined as open chromatin, H3K4me3 or H3K27ac marks detected in normal ovarian and/or fallopian cells

* There are 16 genes in this region: *ABO, SURF6, MED22, RPL7A, SNORD24, SNORD36B, SNORD36A, SNORD36C, SURF1, SURF2, SURF4, C9orf96, REXO4, ADAMTS13, CACFD1, SLC2A6*, however all SNPs are within or upstream of *ABO* or upstream of *SLC2A6*.

** Trend p=0.067